Physician profile
Amanda Zuber
NPI 1215493747
$2,239.83
in general payments reported to CMS, 2019-2025
25 companies · $393 in 2025
The $393 reported for 2025 was more than what a typical Gerontology (Nurse Practitioner) provider received nationally (typical 2025 total: $180).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,387 · 2022: $39.23 · 2024: $420 · 2025: $393.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $813.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $813.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $440.19 | 2021-2024 | Evenity, Tepezza, Prolia |
| Abbvie INC. | $348.67 | 2021 | |
| Astrazeneca Pharmaceuticals Lp | $218.33 | 2021-2025 | Saphnelo |
| Janssen Biotech, INC. | $191.39 | 2021-2025 | Tremfya |
| Glaxosmithkline, LLC. | $124.59 | 2024-2025 | Nucala |
| Lilly USA, LLC | $122.78 | 2021 | |
| Novartis Pharmaceuticals Corporation | $121.91 | 2021 | |
| Pfizer INC. | $92.08 | 2021-2025 | |
| Genentech USA, INC. | $82.27 | 2021-2025 | Ocrevus Zunovo, Ocrevus |
| E.R. Squibb & Sons, L.L.C. | $44.28 | 2021 | |
| Octapharma USA, INC. | $42.25 | 2025 | Octagam Immune Globulin (Human) |
| Lundbeck LLC | $41.04 | 2025 | Vyepti |
| Ucb, INC. | $40.96 | 2021 | |
| Mallinckrodt Hospital Products INC. | $40.53 | 2021 | |
| Boston Scientific Corporation | $39.23 | 2022 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $32.57 | 2024 | |
| Tg Therapeutics, INC. | $31.16 | 2025 | |
| Sobi, INC | $30.89 | 2025 | |
| Hikma Pharmaceuticals USA | $29.06 | 2021 | |
| Alexion Pharmaceuticals, INC. | $24.82 | 2025 | Ultomiris |
| Alnylam Pharmaceuticals INC. | $23.89 | 2024 | Onpattro |
| Actelion Pharmaceuticals US, INC. | $21.69 | 2021 | |
| Radius Health, INC. | $20.74 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $17.87 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $16.64 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Zuber listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.